Dr. Anseth was born and raised in Montana. He attended Concordia College and the University of North Dakota School of Medicine. He completed an orthopedic surgery residency in Flint, MI and a fellowship in Adult Reconstruction in La Jolla, CA. Dr. Anseth joined Twin Cities Orthopedics in 2005. He currently leads the Total Joint Service Line. During his time with TCO, Dr. Anseth has helped develop joint replacement centers and bundled payment programs. As the Total Joint service line lead, he is part of the team evaluating new technologies in joint replacement to understand the benefits as well as the risk.

Mr. Bailey's 20-year career in the business of healthcare spans the provider, payer and medical device industries. His work in market access and reimbursement of medical devices has touched orthopedics, cardiac surgery, biologics and neuromodulation. His current role as VP Market Access at SetPoint Medical will establish reimbursement for the world's first neuroimmune modulation therapy to treat autoimmune conditions - the SetPoint System.

Maria Berkman, MD, MBA is a Partner at Vensana Capital, to which she brings over 20 years of venture, clinical, and consulting experience. Prior to Vensana, Maria was the Head of MedTech at Broadview Ventures and Managing Director of Longview Ventures – affiliate funds dedicated to early-stage investments in cardiovascular disease and stroke. Maria currently serves on the boards of Alleviant Medical, AtaCor Medical, and Vectorious Medical Technologies, and previously on the boards of Apama Medical (acquired), CardiAQ (acquired), Remedy Therapeutics (acquired), Capricor Therapeutics (IPO), Lyra Therapeutics (IPO), CroíValve, XII Medical, Puzzle Medical, and Relief Cardiovascular. Prior to her venture career, Maria was a management consultant with Monitor Group and trained at Mass General Brigham’s Newton Wellesley Hospital. She concurrently earned an MD from the UCLA School of Medicine and an MBA from the Anderson School of Management at UCLA, graduating Alpha Omega Alpha. Outside of her venture career, Maria serves on the Board of Advisors at the Boston Museum of Science and as a member of the Acquisitions Circle at the Institute of Contemporary Art / Boston.

Joe is a Managing Partner at 3x5 Partners, a venture capital firm that collaborates with passionate entrepreneurs who are developing solutions in response to global healthcare and climate needs. Previously, Joe was a Managing Director at SightLine Partners, where he helped raise $250M+ over 15 years to invest in the healthcare sector. During his tenure at Sightline, Joe served on numerous boards and completed transactions in over 50 companies with his partners. He began his career at Bremer Asset Management and is based in the Twin Cities.

Milo Bissin is Southwest and Central US Market Manager for Silicon Valley Bank’s Life Science and Healthcare group. Based in San Diego, he is responsible for providing his clients with valuable advice and insights about their relevant sector and delivering customized financial solutions leveraging SVB’s unique platform. In his 18+ years with SVB, Milo has worked with private and public companies of all life stages across the technology and life science sectors and originated several hundred million dollars in new loans to support his clients and increase their probability of success. Milo holds a bachelor’s degree in Finance from Santa Clara University.

Mike Blue joined HistoSonics as President, CEO and Board Director in January 2017 and has more than 25 years of leadership experience within the medical device sector, almost exclusively in interventional oncology. Since his start, HistoSonics has raised over $300M in equity financings resulting in significant value creation, successfully completed pivotal clinical trials in multiple indications, opened a new corporate headquarters and manufacturing facility in Minneapolis, MN, and is now commercializing the company’s breakthrough Edison Histotripsy Platform around the world. Prior to joining HistoSonics, Mike led the commercial organizations at NeuWave Medical, acquired by Johnson & Johnson in 2016, and superDimension, acquired by Covidien (MDT) in 2012. Mike started his career in consulting as an analyst for Anderson Consulting (Accenture).

Dr. Allen W. Burton is medical director of Abbott’s neuromodulation business, inclusive of Abbott’s neurostimulation and chronic pain management product portfolios. He is a board-certified anesthesiologist with an added certification in pain management and brings nearly 20 years of experience in patient care to Abbott, alongside a strong background leading large-scale clinical research programs. Dr. Burton joined Abbott in October 2015 and served as principal investigator for the ACCURATE and SUNBURST clinical trials. Prior to joining Abbott, he served as Chairman of the Department of Pain Medicine at the University of Texas MD Anderson Cancer Center from 2000-2011. From 2011-2015, Dr. Burton practiced privately with Houston Pain Associates, where he directed clinical research and participated in many clinical trials. Dr. Burton obtained his bachelor of science at the University of Notre Dame, medical doctorate at Baylor College of Medicine, and completed his residency at Brigham and Women’s Hospital, Harvard Medical School. He has published more than 50 peer-reviewed articles and authored two text books, taught and lectured nationally and internationally, and played an active leadership role among numerous pain societies and editorial boards.

Successful, profit driven healthcare executive with over 20 years progressive experience in management, sales, clinical, and business development. Visionary leader and team player with stellar track record of superior performance in sales productivity, team building, customer relationship building, and account development. Notable interpersonal skills with a capacity to reach all levels of field personnel, management, and physicians. Multi dimensional, innovative strategist focused on consistent achievement of objectives. Recognized for an outstanding work ethic, integrity, and commitment to corporate goals and directives. Eternal optimist with a focused "can-do" attitude.

Mr. Cohen is responsible for equity research coverage of medical technology and healthcare services. He has 19 years of experience directly involved in the worldwide financial markets, of which he has spent the past 11 years directly involved with healthcare research and sales. Prior to joining Ladenburg Thalmann, he was a Senior Healthcare Research Analyst at C.K. Cooper & Company focusing upon the biotechnology, medical technology, and healthcare services segments. Mr. Cohen also served as a healthcare research analyst at Jesup & Lamont Inc., where he focused upon medical technology with sector specialization within Cardiology, Vascular, Orthopedics and Diabetes. Prior to equity research & sales, he spent seven years trading and managing fixed‐income and equity derivative products at Cantor Fitzgerald, Sanwa Securities and the American Stock Exchange. Mr. Cohen holds a B.S.E. in Systems Engineering from the University of Pennsylvania and an M.B.A. from the University of Miami. He has also served as an Adjunct Professor of Business & Management at Lynn University teaching Economics, Management, and International Business.

Hutch Corbett joined Armentum Partners in 2014 and leads transactions in both the healthcare and technology sectors. He has over 20 years of experience as an investment banker, operator, and lender. Previously, Hutch served as a senior lender at TriplePoint Capital, the Chief Financial Officer of Nexus Dx (a Kleiner Perkins and Bay City Capital–backed start-up), and a healthcare investment banker. Hutch began his investment banking career at Morgan Stanley, helped build the West Coast team at Thomas Weisel Partners, and served as a Managing Director and Head of West Coast Life Sciences in Oppenheimer’s (previously CIBC) healthcare investment banking group in Menlo Park. Hutch received a Master of Business Administration from the University of Virginia Darden Graduate School of Business and a Bachelor of Science in Business Administration from the University of Colorado (Boulder). Hutch and his wife Christine live in Los Altos. When not raising capital on behalf of his clients, he enjoys cheering on his three boys in their various sporting endeavors.

Josh is a true digital pioneer, getting his start in the digital marketing space in 1997 for an internet radio startup. With nearly 28 years of experience he's seen everything from the .com boom and doom, the social media revolution and now the AI transformation. He's worked with everything from medtech startups to enterprise health system providers both locally and nationally. His focus has always been on the measurability of the digital space and driving growth through digital marketing.

Andrew J. Danielsen serves as Chief Business Development Officer at Mayo Clinic, where he oversees the licensing, technology development, venture investment and business development functions. Collectively, these groups work to identify, develop and commercialize Mayo Clinic intellectual property. These activities generated over $100 million in revenue for Mayo Clinic in 2020. Prior to joining Mayo Clinic Ventures in 2002, Mr. Danielsen conducted research at Mayo Clinic where he worked to identify therapeutic targets in breast and ovarian cancer. Mr. Danielsen serves on several committees throughout Mayo Clinic, including the Executive Subcommittee of the Medical-Industry Relations Committee. He is also a member of multiple groups responsible for funding innovative new technologies or startup companies, including the Mayo Clinic Venture Fund Investment Committee, the Discovery Translation Program, and the Department of Business Development Investment Committee. Mr. Danielsen received his B.S. in biochemistry and molecular biology from the University of Wisconsin-Eau Claire and his M.S. in molecular biology from Mayo Clinic Graduate School of Biomedical Sciences.

A Partner at Fox Rothschild, a national AmLaw 100 law firm, Kathryn Dehn advises startups and emerging companies throughout their corporate lifecycles – from company formation and capital raising to their eventual exit. She works with founders, management teams and boards in the role of outside general counsel, advising on strategic matters and negotiations.

Kathryn has extensive experience representing medical technology companies with entity selection and initial formation, capital raising, technology licensing, clinical trial agreement negotiation, HIPAA compliance, data privacy and M&A transactions. In addition to her work with startup companies, Kathryn represents venture capital funds with respect to their portfolio investments.

Jon Demchick is Co-Founder and Principal at Gilmartin Capital, where he focuses on growth equity and venture investments in the medical technology sector. With over 15 years of healthcare experience, Jon brings a multidisciplinary perspective spanning investing, equity research, and consulting. Prior to founding Gilmartin Capital in 2022, he was a Research Analyst at Millennium Management and an Executive Director at Morgan Stanley, where he covered a broad range of public medtech companies. He began his career in healthcare consulting at FTI Consulting, advising hospital systems on cost efficiency and strategic planning. Jon earned a B.S. in Economics with concentrations in Finance and Operations from the Wharton School at the University of Pennsylvania.

With more than three decades of experience in reimbursement, Jo has held diverse positions across provider, medical device companies, and health plan organizations. In her role as a consultant, she focuses on expediting the adoption of innovative technologies by integrating coding and payment policy initiatives, including applications for HCPCS/CPT and ICD-10 coding. Additionally, she employs strategic advocacy tactics to influence the payer coverage landscape. Jo also serves as the CPT and RUC staff member for the American Society of General Surgeons.

Mark has dedicated over 25 years of his career to the healthcare industry, primarily concentrating on medical technology, provider reimbursement, and health economics. He possesses extensive expertise in payment policy, particularly regarding new technologies, including CMS's New Technology Add-On Payment, Transitional Pass-Through, and New Technology APC programs. Mark has led reimbursement initiatives for multinational corporations as well as startups, and as a consultant, he has assisted numerous clients in developing and implementing effective reimbursement strategies.

Mark DuVal, JD, FRAPS, is CEO of DuVal & Associates, P.A., a law firm dedicated to counseling companies in the medical device, pharmaceutical, biotech, food, and nutritional supplement industries.

His practice includes providing strategic regulatory advice, developing compliance programs, designing, and implementing sophisticated marketing programs, counseling on reimbursement matters, conducting sales training and interfacing extensively on behalf of companies with the FDA with relation to product approvals and clearances, clinical trial negotiations, approvals, policy arguments, appeals, etc.

Prior to founding the firm, Mark was general counsel for 3M Pharmaceuticals and Drug Delivery Systems working both domestically and internationally. He was on assignment for 3M Health Care Systems, Ltd. In Europe based out of the United Kingdom. He then worked at Medtronic in Corporate Compliance for FDA, Anti-kickback, False Claims Act, HIPAA & HITECH, and other advice related to the FDA-regulated industry.

Mark earned his Juris Doctor from the William Mitchell College of Law where he served as executive editor on the law review, and his Bachelor of Arts in Public Administration from St. Cloud State University. Mark has served on various boards including the Minnesota BioBusiness Alliance, Minnesota Biosciences Council, The Food and Drug Law Institute and has been a former Chairman of the Minnesota State Food, Drug, and Medical Device Section of the Minnesota State Bar Association. He is also on the Board of Advisors of the Masters in Regulatory Affairs Services program at St. Cloud State University.

Mark is a frequent national speaker and writer on issues relating to product approvals/clearances; combination products, product advertising and promotion, Antikickback, and False Claims Act (reimbursement) matters.

James Eadie, MD, MBA is a Managing Director at Santé, where he leads the firm’s medical device investment practice. Since joining Santé in 2009, James has focused on partnering with entrepreneurs to build companies from the earliest stages of inception through clinical development and early commercialization. Together with the Santé team, James has a strong track record of helping build transformational companies, including TVA Medical (acquired by BD Bard), and Claret Medical, Millipede, and Farapulse (all acquired by Boston Scientific), as well as Laminar (acquired by Johnson & Johnson). A board-certified emergency medicine physician, James brings clinical depth and operational insight to his investment work. Prior to his venture career, he served in the U.S. Air Force, where he held academic and leadership roles, including Vice Chair of Emergency Medicine at a Level I trauma center. He completed two combat deployments to Iraq, serving in critical care and trauma care commands. James remains active in the healthcare innovation ecosystem, advising translational research programs and mentoring early-stage medical technology teams. He earned his MD from the Harvard–MIT Program in Health Sciences and Technology (HST), his MBA from the University of Texas McCombs School of Business, and his BS in Bioengineering from the University of Michigan. He completed his residency at Massachusetts General Hospital and Brigham and Women’s Hospital.

Jim Erickson, Chief Financial Officer of Saluda Medical, has more than 20 years of finance, accounting, and leadership experience. Prior to joining Saluda, he served as CFO and Head of Marketing at Monteris Medical, a medical device company focused on developing neurosurgical laser ablation capital and disposable systems. Prior to joining Monteris, Mr. Erickson held various roles of increasing responsibility at Tornier, including Vice President, Global Controller and Vice President, Global Finance. Following the announcement of Tornier’s merger with Wright Medical in 2015, he also served as Vice President, Integration, where he was a member of the senior executive management team of the combined company and led the global Integration Management Office. He began his career in the assurance and advisory services practice with Ernst & Young, LLP and holds a Bachelor of Business Administration degree in accounting from the University of Iowa.

Morgan Evans is an engineer by training, an entrepreneur by nature, and an executive by necessity. With nearly two decades’ experience in the full lifecycle of MedTech product development and delivery - from idea through regulatory approval to commercialization - she works from first-hand knowledge of how to conceive and design technically complex and highly regulated products, attract talent and build teams, and establish sustainable companies. The throughline in Morgan’s MedTech career is an iterative style of problem-solving that focuses one eye on the immediate task, and the other eye on how a process can be improved. Needing technical expertise for her own product development, Morgan built a network of collaborators that continues to work together through AVIO Medtech Consulting. Finding high age and gender hurdles to her early effort to raise funds, she found partners with whom to form Engage Venture Partners to open doors to angel and early series investors for entrepreneurs, and to make direct investments using special purpose investment vehicles that provide flexibility and collaborative due diligence. She remains a hands-on leader in an innovative medical device company — Agitated Solutions, Inc (ASI). ASI’s initial product received IND clearance for their Phase 3 clinical trial and expects to complete the trial by the end of the year. The same product is also commercially available in Canada. ASI has a portfolio of new products in the development pipeline related to enabling and enhancing diagnostic ultrasound. Morgan is involved in a variety of organizations and forums exploring MedTech development, women’s business leadership, and entrepreneurial activity. As a nearly lifelong basketball player and coach, Morgan volunteers with school teams in her home community, as well as with AAU summer programs. But that’s just for the sheer joy of it.

Bryan serves as President of DuVal & Associates. He specializes in advising medical device, pharmaceutical and nutritional supplement companies on FDA legal, regulatory and compliance matters. His practice includes providing legal/regulatory advice for the design and implementation of sophisticated marketing and compliance programs under the Food, Drug & Cosmetic Act, the Anti-Kickback Statute, the False Claims Act, the Eliminating Kickbacks in Recovery Act, the Physician Payments Sunshine Act, and HIPAA. Bryan also advocates on behalf of clients with the FDA and the Office of Inspector General relating to medical product submissions and appeals, promotional activities, inspections, and enforcement matters. Additionally, Bryan counsels companies on compliance and regulatory due diligence matters, conducts compliance and due diligence assessments, and provides national compliance trainings to help clients satisfy their regulatory obligations and achieve their business objectives. Finally, Bryan advises medtech companies regarding their HIPAA and GDP obligations as it relates to patient privacy, clinical trials, and medical device development. Prior to joining DuVal & Associates, Bryan enjoyed a fourteen-year career as a shareholder at a Minneapolis law firm. As a former trial attorney, Bryan is experienced in trial and appellate matters, including complex commercial and business disputes, intellectual property litigation, including patent and trademark litigation, and counseled clients on regulatory, compliance and business ethics matters. Bryan is a 2006 graduate from the University of St. Thomas School of Law. He obtained an LL.M. degree in Corporate Compliance and Organizational Ethics from the University of St. Thomas School of Law in 2015 and obtained a Cybersecurity and Privacy Law Certificate from Mitchell Hamline School of Law in 2019.

Adam Foresman is the Co-Founder and CEO of Ryden Solutions, a continous MedTech compliance assessment platform. He has over 17 years of experience in the medical device industry including design, manufacturing, quality, compliance and cybersecurity roles from startup to Fortune 1000 organizations. He led the largest dental diagnostic AI MedTech company, VideaHealth, from pre-revenue through Series B getting over 30 detection aides FDA cleared where the Harvard Business School wrote an Executive MBA case study highlighting how he used quality & compliance to create a strategic advantage. Adam has written multiple articles, speeches, and contributed to textbooks on life science technology quality. He has a Masters in Engineering & MBA along with ASQ & RAC certifications.

Jan founded Arboretum on the premise that innovation is key to delivering value in healthcare, a principle she developed working in the medical device industry for over two decades. Her investments focus on promising medical technologies that enable meaningful healthcare system savings while maintaining great clinical outcomes. Jan has led and held board roles in more than 25 investments across six funds including notable exits with HandyLab (acquired by BD), Esperion (Nasdaq: ESPR), NxThera (acquired by Boston Scientific), CardioMEMS (acquired by St. Jude Medical), and NeuMoDx (acquired by QIAGEN). Jan served on the National Venture Capital Association’s Board of Directors from 2015-2020 and in her last year, was the Board Chair. As chair, she prioritized industry-wide diversity initiatives and was instrumental in driving small business access to CARES Act financial assistance programs early in the COVID pandemic. In 2020 she testified at the US Senate on “Expanding American Entrepreneurship Outside Traditional Hubs”. Jan was recently awarded the Venture Vanguard Award by the NVCA (2023). Previous awards include: USA Top Women Dealmakers Award (2021), MichBusiness Women Leaders Hall of Fame (2020), Crain’s 100 Most Influential Women (2021, 2016), and as Crain’s Newsmaker of the Year (2015). She earned a BS in Bioengineering from the University of California at Berkeley and an MBA from the Wharton School at the University of Pennsylvania.

Dr. Archelle Georgiou is a physician who wakes up every day thinking about how to empower people to make informed medical decisions. She is the author of Health Care Choices: 5 Steps to Getting the Medical Care You Want and Need, and she hosts a podcast, Speak Up For Your Health. With over 16 years of experience as a TV health journalist and a weekly segment on KSTP-TV (ABC), Archelle has produced and aired more than 1000 segments that simplify complex healthcare information for consumers. For people that need more help than her shows and her book to research and navigate their medical care, Archelle offers one-on-one health advocacy and coaching services. Archelle’s perspective has evolved over her 30+ year career with her leadership positions in managed care, investment banking, and medical device companies. This includes serving as Chief Medical Officer and senior executive at UnitedHealth Group and Chief Health Officer of Starkey Hearing Technologies. She currently serves as Immediate Past-Chair of the Board of Directors at Children’s Hospital of Minnesota, Board Member and Governance Chair for Nuwellis (Nasdaq: NUWE) and Executive in Residence at the University of Minnesota's Carlson School of Management. In 2022, Archelle was selected to deliver the “Healthy People, Healthy Planet” presentation during the United States’ bid to host the 2027 Worlds Expo. She was also the medical correspondent on the Blue Zones expedition that explored the secrets of healthy aging and longevity in Ikaria, Greece. Archelle graduated from the Johns Hopkins School of Medicine and was board-certified in Internal Medicine. She lives in New York and Minneapolis.

Mike is a Managing Director and Industry Executive with J.P. Morgan Securities LLC, based in Minneapolis, MN. Mike leads the Life Sciences Commercial Banking team across the Midwest, Intermountain, and Canada regions and has also been tasked with interim leadership of the West Coast Life Sciences team. The focus of the team is to provide innovative financial products and networking to start-up through small cap companies in the space. Mike’s team specifically focuses on companies in the medical device, pharmaceutical, biotech, tools and diagnostic, specialty contract manufacturing and pharma services spaces. With nearly 25 years of experience, Mike’s career at J.P. Morgan includes structuring and implementing wide-ranging credit transactions and managing relationships with a range of life science, healthcare, manufacturing and industrial corporations, large research universities and private colleges. He has worked with taxable and tax-exempt financing structures, syndications and participations for these entities. He also brings expertise in treasury management for companies looking for efficient ways to manage their operations. Mike received a B.B.A. in Finance, Investments, and Banking from the University of Wisconsin – Madison. Mike is currently on the Board of Directors of University Enterprise Labs in St. Paul, Minnesota. He is an advisor to the University of Minnesota’s Discovery Capital group, a member of the University of Minnesota’s Business Advisory Group, and a mentor for Creative Destruction Lab at the University of Wisconsin - Madison.

Ms. Hance currently serves as the Associate Director of Research at Ladenburg Thalmann & Co. Inc., an Osaic Advantage Company. In this role, she manages a team, creates and implements business processes, and maximizes overall efficiency. She is also responsible for building detailed and multi-functional financial models, composing comprehensive research reports (including initiations and event-driven updates), conducting in-depth research on publicly traded companies within the healthcare sector, arranging introductory calls with both private and public companies, and attending scientific conferences related to orthopedics, spine, energy delivery (stimulation, radiation), visualization, imaging, robotics, and cardiology. Since joining the firm as an intern in 2017, Ms. Hance has been promoted multiple times: first to Associate, where she served for over three years, then to Senior Associate, and then Vice President. She holds Series 7, Series 86, and Series 87 licenses. She earned a BS in Entrepreneurial Studies with a minor in Digital Product Design from Lynn University in South Florida and an MBA from the University of Florida, Gainesville.

Experienced investor with two decades of fundamental equity investing experience and a track record of outperformance in the healthcare, energy, and consumer sectors on long-only and long/short platforms. Areas of expertise include medical device, life science tools, diagnostics, and healthcare services. Passionate about impact and transforming healthcare delivery.

Drew is a proven medical device operating executive with broad functional, geographic and sector experience. Drew served as CEO of Inari Medical from 2023 until its acquisition by Stryker Corporation in 2025 for $5 billion. From 2020-2022, Drew was Chief Operating Officer of Inari Medical leading its day to day business operations. From 2017-2019 he served as Inari’s Chief Commercial Officer. Prior to Inari, from 2012-2016 Drew served as the VP of Commercial Operations at Sequent Medical where he led the commercialization strategy for the WEB Aneurysm Embolization system from early prototype to broad adoption in the European market. Sequent was acquired by Terumo Corporation in July 2016 for $380 million. Prior to Sequent, Drew spent 11 years at Medtronic. His roles at Medtronic included the VP of Marketing for the AF Solutions business, VP of Clinical and Regulatory for the AF Solutions business and Director of Investor Relations. Drew also spent three years on an expatriate assignment in Europe leading the launch of Medtronic’s first drug eluting coronary stent. Prior to Medtronic, he spent four years at ABN AMRO bank in Chicago focused on healthcare transactions. He holds a B.B.A. in Finance from the University of Wisconsin and an MBA from Harvard Business School.

Kevin Hykes is the President and CEO of CVRx and is an accomplished medical device industry executive with over 30 years’ experience successfully commercializing novel therapies on a global basis. Before joining CVRx in February 2024, Kevin was President and CEO of Augmedics, Inc., a pioneer in augmented reality surgical navigation. Prior to Augmedics, Kevin was President and CEO of Bardy Diagnostics, a leading provider of ambulatory cardiac monitoring and digital health solutions which was acquired by the Hillrom Corporation in August of 2021. Before Bardy Diagnostics, Kevin was President and CEO of Relievant Medsystems, a privately held medical device company commercializing the Intracept® procedure for the treatment of chronic lower back pain, later acquired by Boston Scientific in 2023. Prior to Relievant Kevin was Chairman and CEO of Metavention, Inc., a privately held medical device company focused on the development of interventional therapies for the treatment of type 2 diabetes. Prior to Metavention, Kevin was President and CEO of Cameron Health, developer of the subcutaneous implantable defibrillator, until its acquisition by Boston Scientific in 2012. Prior to Cameron Health, he was the Chief Commercial Officer of Visiogen, Inc, a privately held ophthalmology company which was acquired by Abbott Medical Optics in 2009. Previously, Kevin spent sixteen years at Medtronic, where he held leadership positions in the CRM, Neurostimulation, and Cardiac Surgery businesses in the US and Europe. Kevin is currently a Venture Advisor with Vensana Capital, a board member of AdvaMed Accel, and previously served on the boards of CVRx (CVRX), Metavention (private), Hansen Medical (HNSN) and Veran Medical Systems (private). Kevin received his MBA from Northwestern University and a BBA in Information Systems from the University of Wisconsin.

With nearly two decades at Medical Alley Association, he served in various leadership roles, most recently as Vice President of Innovation and Head of Medical Alley Starts. Frank has been instrumental in advancing the medtech sector, connecting companies with partners, investors, and key talent. He has a proven track record in international business development and strategic services, particularly for startup companies. Frank holds a Master of Political Leadership from the University of Minnesota Duluth and a Bachelor of Arts in Political Science from the University of Minnesota. He is known for his dedication to fostering innovation and his deep connections within the medtech community.

Justin Klein, MD, JD, is a co-founder and Managing Partner at Vensana Capital, a venture capital & growth equity investment firm dedicated to partnering with entrepreneurs who seek to transform healthcare with breakthrough innovations in medical technology. Justin was previously a partner at NEA, one of the largest and most active venture capital firms in the world. Justin also worked at the Duke University Health System where his experience included roles in strategy, finance and operations as Duke built one of the nation’s first integrated healthcare delivery systems. Justin currently or previously served on the board of directors of Cartiva (acquired), ChromaCode, CV Ingenuity (acquired), Epix Therapeutics (acquired), FIRE1, Intact Vascular, Metavention, Personal Genome Diagnostics, PhaseBio Pharmaceuticals (IPO), Relievant MedSystems, Senseonics (IPO), Topera (acquired), Ulthera (acquired), VertiFlex, Vesper Medical, and VytronUS. Justin graduated with an AB in Economics, a BS in Biological Anthropology & Anatomy, and a Minor in Chemistry from Duke University. He also concurrently earned his MD from the Duke University School of Medicine and his JD from Harvard Law School.

A Partner at Fox Rothschild, an AmLaw100 law firm, Patrice Kloss serves as Co-Chair of the firm’s national Medical Technology practice group. With deep industry knowledge, Patrice advises medical technology companies, digital health care companies, other emerging businesses and venture capital investors in commercial and financing matters, including: • venture capital financings • private placements • mergers and acquisitions • venture debt and credit facilities • securities compliance

Patrice also guides lenders in commercial loan transactions, including $100 million+ loan facilities, advises clients on equity financing structures and clinical trial agreements, and frequently counsels boards of directors on fiduciary duties and corporate governance obligations.

Mike brings over 35 years of broad and strategic healthcare leadership experience in medical devices, pharmaceutical, biotechnology, clinical research, and payer economics. He currently serves as the President and Chief Executive Officer of Francis Medical, a start-up medical device company developing water vapor technology for treating prostate cancer. Before Francis Medical, Mike was the Chief Marketing Officer and Senior Vice President of International for NxThera, a start-up medical device company purchased by Boston Scientific in 2018. He has also served as Vice President and General Manager of the Prostate Health business unit of American Medical Systems, which developed and commercialized medical device solutions to treat BPH, prostate cancer and stone disease. Mike has been involved with over four strategic exits over his career. Mike received his MBA from the OPUS College of Business, University of St. Thomas in St. Paul, Minnesota, and a Bachelor of Science in physics and chemistry from the University of South Dakota.

Mike brings over 35 years of broad and strategic healthcare leadership experience in medical devices, pharmaceutical, biotechnology, clinical research, and payer economics. He currently serves as the President and Chief Executive Officer of Francis Medical, a start-up medical device company developing a novel technology using water vapor for treating prostate cancer. Mike has been involved with over four strategic exits over his career

It is hard to innovate, harder to show it works first and then works consistently, hardest to find the right people to work with to make it happen. Everything is worth it when you see someone's life change as a result. Changing lives one person at a time - this is my passion.

Chris focuses his consulting practice on the intersection of clinical evidence, regulatory requirements, and payer coverage policies to support product approval requirements and demonstrate value to payers and providers. A biostatistician by training, Chris has successfully negotiated study designs with FDA and several OUS regulatory agencies. Chris has over 25 years of experience in the medical device industry and has supported the development of medical devices, biologics, and pharmaceuticals. Prior to joining DuVal & Associates, Chris was a Partner at the JD Lymon Group, a Minneapolis-based reimbursement and market access consulting firm, where he focused on evidence development initiatives to support positive coverage arguments. He spent the prior 12 years at RCRI, a Minneapolis-based device CRO, where he held various executive positions including roles overseeing corporate operations, biostatistics, and market access. Before that Chris was a biostatistician at 3M Company working with 3M Pharmaceuticals and multiple medical device divisions. Chris holds a B.A. in Mathematics from St. Olaf College, and an M.S. in Applied Statistics from Florida State University. He speaks routinely on evidence strategies and clinical study design to support pre- and post-approval requirements and has served on the community faculty of both Metropolitan State University and the St. Cloud State University Masters of Regulatory Affairs program. He is also a co-founder and Board member of JDL Access, LLC, a prior authorization and patient appeals firm based in Minneapolis.

My mission is to help people live longer and feel better focused on arrhythmias (Atrial Fibrillation). I'm seeking to amplify that impact by adding artificial intelligence (AI) to my skill set. My tools are innovation blending engineering, medicine, and business insights that I gained through diverse experiences and education. Since college, I have strived to learn about cardiac electrophysiology in the broadest sense—medicine, clinical trials, regulatory pathways, engineering, and the business. I started as an electrical engineer working on a wireless EKG at MIT. Seeing how it helped patients inspired me to go to medical school and become a cardiac electrophysiologist. I’m licensed to practice medicine in Minnesota, Washington DC, Virginia, Ohio, and California. After training at Mayo, I worked in an academic practice for 6 years. I started-up 2 companies and then spent 9 years in the medical device industry. While my passion is electrophysiology, I have worked in multiple areas of cardiology. I have been credited with 14 patents in the space, which generates $2B in revenue and touches 500K patients a year. I am unapologetic about challenging accepted wisdom. An example includes disproving that lesions have to be transmural to get isolation around the pulmonary veins. This insight led to the understanding of High Power Short Duration Ablation, which became a core organizational competitive differentiator for St. Jude. I am a constant learner and every year try to learn a new skill (piano and golf are examples). Because I have found the greatest innovation comes from the intersection of fields, I have sought new work experiences in adjacent fields to medical device. Most recently, I was the Chief Strategy Officer at a state-wide $6B hospital system. This helped me better understand the challenges hospitals face and how they make decisions. It also exposed me to diverse fields like neurology and cell therapy, which could potentially help in arrhythmia care. During my 2-years as a hospital administrator, I realized that arrhythmia care could vary depending on which doctor you saw. Much of therapy is heuristic and image based. At the same time, I was learning more about AI and thought AI would be a great way to equalize care of arrhythmias. At Neutrace, we seek to give every arrhythmia patient world-class care.

Michael “Mike” Mahoney is Chief Executive Officer of Boston Scientific Corporation and Chairman of the company’s Board of Directors. Boston Scientific is a global medical technology leader with approximately $12.7 billion in annual revenue and commercial representation in more than 130 countries. Under Mike’s leadership, Boston Scientific is delivering on its mission to transform lives through innovative medical solutions that improve the health of patients around the world. The company’s team of more than 45,000 global employees reaches over 33 million patients each year, providing a range of technologies and solutions that span cardiovascular interventions, structural heart, electrophysiology, endoscopy, neuromodulation and urology, and women’s health. Since joining Boston Scientific, Mike has focused the company on addressing the needs of the evolving healthcare landscape by driving improvements to patient outcomes and increasing healthcare economic efficiency and access. Under his leadership, Boston Scientific has brought many transformational medical devices to market while creating significant value to its shareholders. Mike’s career spans more than 25 years of success building market-leading medical device, capital equipment and healthcare IT businesses. Prior to Boston Scientific, he served as Worldwide Chairman of the Medical Devices and Diagnostics (MD&D) division of Johnson & Johnson. Prior to joining Johnson & Johnson, Mike was President and Chief Executive Officer of Global Healthcare Exchange (GHX). For the first 12 years of his career, Mike advanced through a series of leadership roles at General Electric Medical Systems, including General Manager of the company’s Healthcare Information Technology business. Mike serves on the Board of Directors of Baxter International, the Board of Boys & Girls Club of Boston and as the chair of the Board of Governors of Boston College CEO Club. He earned his B.B.A. in Finance from University of Iowa and his M.B.A. from Wake Forest University. He is married and has three children.

Mary’s career has been built on transforming MedTech ideas into commercial successes, from pioneering innovative devices across multiple disease states to leading major organizational shifts, she consistently delivers results that drive business growth and industry change. Most recently she spearheaded a significant branding and market initiative, successfully transforming bioelectric wound care technology from an exclusively hospital-based, to a direct-to-consumer solution. This required a dramatic paradigm shift - new channels, messaging, analytics, and a deep understanding of evolving consumer behavior in post-pandemic healthcare.

Steven V. Manoukian, MD, FAHA, FACC, FSCAI is Senior Vice President, HCA Healthcare, Nashville, TN. Dr. Manoukian was recruited in 2008 and leads Service Lines & Clinical Resiliency for HCA enterprise-wide, one of the largest healthcare systems, across its over 180 US and UK facilities. Service Lines provide focused expertise, comprehensive strategic skills, leadership and collaboration, which inform clinical, business and operational decision-making. Clinical Resiliency is at the intersection of clinical quality, costs and value achieved for patients and other stakeholders. Other HCA responsibilities include the Senior Leadership, Operating and Research Institute Steering Committees. Prior HCA roles include: Vice President in the Clinical Services Group, Medical Director of Cardiovascular Services, Director of Cardiovascular Research and practicing interventional cardiologist at Centennial Heart, all in Nashville, Tennessee. Before joining HCA, Dr. Manoukian spent 19 years at Emory University School of Medicine in Atlanta, including fellowships in Cardiology and Interventional Cardiology and 15 years on the faculty, including as Director of Interventional Cardiology at Emory University Hospital-Midtown. His residency and chief residency were at the State University of New York at Stony Brook and he is a graduate of New York University School of Medicine. Dr. Manoukian received his undergraduate degree from St. John’s University in New York. Dr. Manoukian is an experienced academician and clinical researcher, with numerous leadership roles and publications who lectures at national society, clinical and research meetings. His awards include the Emory Excellence in Teaching Award and American Federation for Clinical Research Trainee Investigator Award. He is a Subject Matter Expert for the FDA’s Total Product Life Cycle Advisory Program (TAP). Dr. Manoukian was selected as the American Heart Association (AHA) 2024 Healthcare Volunteer of the Year. He is the primary architect of the joint AHA, HCA Healthcare and HCA Healthcare Foundation’s Getting to the Heart of Stroke initiative, which is enhancing collaboration between neurology and cardiology providers, improving diagnosis of stroke etiology and outcomes, while reducing stroke recurrence. Dr. Manoukian serves or has served in numerous capacities with national organizations, including the American College of Cardiology (ACC) NCDR ACTION Registry Steering Committee; Society of Thoracic Surgeons (STS)/ACC TVT Registry Stakeholder Advisory Group; AHA Quality Accreditation Science Committee and Advocacy Coordinating Committee; Society for Cardiovascular Angiography & Interventions (SCAI) Development & Industry Relations Committee and Finance Committee; Heart Valve Collaboratory Leadership and the Extracorporeal Life Support Organization (ELSO) Strategic Advisory Council. He is a board observer for viz.ai and VitalConnect. Dr. Manoukian was a Medical Reporter for FOX television in Atlanta from 1998-2008.

Sara’s career has centered on building and scaling impactful brand and marketing strategies across technology, healthcare and consumer industries. With over a decade of experience leading cross-functional teams and guiding campaign strategy, she’s helped national and global organizations—from UHG and Humana to Be The Match and Post Consumer Brands—navigate complexity and deliver results. Most recently, she played a pivotal role in bringing PowerHeal directly to consumers, reshaping the brand, messaging, and go-to-market strategy in a rapidly evolving consumer landscape.

Juan-Pablo Mas is a Partner at Action Potential VC, a bioelectronic medicine fund founded by GlaxoSmithKline, and is based in Santa Cruz, CA. He represents APVC on the Boards of Cala Health, Exo Imaging, Neuspera Medical, Presidio Medical, Saluda Medical, SetPoint Medical, Onc.AI and previously CVRx. Prior to APVC, he was an investor at Lightstone Ventures and Morgenthaler Ventures, where he was a Board observer at Ardian, Twelve, Nuvaira, Cabochon, and Miramar Labs. Prior to investing, Juan-Pablo led R&D and Strategy teams in Medtronic’s CardioVascular Division and was a member of the Global Brand Strategy team at Eli Lilly. Juan-Pablo earned an MBA from the Stanford Graduate School of Business as a Bonini Fellow, an MS in Electrical Engineering from Stanford University, and a BS in EE from the University of Massachusetts. He now serves on the Oversight Committee for Stanford’s Wu Tsai Neuroscience Institute, the Advisory Board for UCSF’s Rosenman Institute, the DEI Advisory Committee for RockHealth.org, and is a co-founder of the non-profit LatinxVC which is dedicated to increasing diversity within venture capital. Juan-Pablo is originally from Puerto Rico and played Division I men’s lacrosse at UMass.

Cheryl Matter, PhD, is the Head of Customer Success at Avenda Health, the developer of Unfold AI, a clinically validated, FDA-cleared prostate cancer mapping and decision support platform that recently received a CPT code and associated payment. In her current role, she drives market adoption by working closely with clinical sites to ensure seamless integration, positive experience and stakeholder value. For the past 20 years, Matter advanced innovative technologies across academic, corporate, payer, and provider environments, integrating user and payer perspectives into product development to improve outcomes and reduce costs. Her previous leadership roles include positions at BCBS MN, Livio Health, LifeSpark Health, and Careforth. Dr. Matter holds a PhD in Molecular and Medical Pharmacology from UCLA.

Dr. Mocco earned his medical degree from Columbia University College of Physicians and Surgeons. During his residency in Neurological Surgery at the Neurological Institute of New York, he also obtained a Master of Science in Biostatistics from Columbia's Mailman School of Public Health. He went on to complete a fellowship in Endovascular Neurosurgery at the University of Buffalo under the tutelage of Dr. Nick Hopkins. Throughout his career, Dr. Mocco has been dedicated to advancing cerebrovascular care through high-quality clinical research and technological innovation. Dr. Mocco has served as a key advisor or Board member for 11 med-tech start ups that have achieved successful exit (acquisition or IPO). He has helped three companies achieve valuations in excess of $1B. He has served as the national or international Principal Investigator (PI) or Co-PI for numerous multicenter prospective trials, including COMPASS (RCT), THERAPY (RCT), PHIL, POSITIVE (RCT), FEAT (RCT), COAST, ACCESS, AMERICA, LARGE, COMFORT, EVERRUN, Barrel, INVEST, and TNK (RCT). Currently, he is a BOD member/observer for Synchron, Imperative Care, Endostream, Kandu, and Protembis and serves as Multi-Principal Investigator (MPI) for the NIH/NINDS StrokeNet Thrombectomy Endovascular Platform (STEP) and Contact-PI for the NIH/NINDS StrokeNet New York City Collaborative Regional Coordinating Center. As Director of the Cerebrovascular Center at Mount Sinai, he oversees ischemic and hemorrhagic stroke care across a network of nine New York Region hospitals.

Carla brings over 30 years of experience in Government Affairs and Market Access. She has provided executive leadership in reimbursement functions for both global companies and startups, including LivaNova, Nevro, AqueSys, and Torax Medical. Her distinctive expertise lies in developing and assembling teams to overcome market access barriers associated with complex therapies. With an entrepreneurial mindset, Carla co-founded JD Lymon Group, as well as JDL Access and Argenta Advisors.

Shockwave Medical - Vice President, Global Market Access & Reimbursement

J.P. Peltier is a managing director and head of healthcare investment banking at Piper Sandler. Peltier has more than 25 years of healthcare investment banking experience at Piper Sandler. He leads a global team of more than 130 healthcare investment banking professionals in offices across the U.S., Europe and Asia. Peltier has extensive experience advising clients on mergers and acquisitions, public and private equity options and other strategic alternatives. Peltier’s prior experience includes five years at HomeServices of America, a Berkshire Hathaway subsidiary, where he served as vice president of corporate development and president of the mortgage banking division. Peltier graduated from the University of St. Thomas and received a Master of Business Administration degree from the J.L. Kellogg School of Management at Northwestern University.

Jeff joined OrbiMed as a Venture Partner in 2018 and currently serves as the Founder and Chief Executive Officer of evanesce Medical. Jeff has over 25 years of medical device experience with executive and strategic roles in companies including Cardialen, ev3 (now Medtronic), Anulex, and Boston Scientific; and financial investment and analysis roles at Black River Asset Management, Foundation Medical, and Dain Rauscher Wessels. Jeff received his B.S. and M.B.A. from the University of Minnesota.

Jacob Robinson, Ph.D., is the co-founder and CEO of Motif Neurotech and a professor of Electrical and Computer Engineering on leave from Rice University. Prior to founding Motif, Jacob published over 60 peer-reviewed publications in neurotechnology and bioelectronics. He now leads Motif in creating miniature implantable devices that act as therapeutic Brain Computer Interfaces to address mood, memory, and cognitive disorders.

Karen Ruszkoski is a seasoned medical device professional with two decades of experience in market access, health economics, marketing, and reimbursement. Karen is currently the Vice President of Market Access and Reimbursement at Volta Medical. Throughout her career, she has worked with leading organizations including Boston Scientific, St. Jude Medical, and Abbott. Karen is a passionate advocate for public health, specifically ensuring all patients have access to innovative technologies. She is skilled at developing evidence generation plans to support value propositions for various stakeholders, including governments, payers, hospital administrators, and physicians. Karen has also successfully influenced reimbursement decisions, including coding, coverage, and payment, for new technologies. Karen holds a B.S. in health management and policy from the University of New Hampshire. She also has a master’s in public health from the University of Michigan. Additionally, she is a certified professional medical coder from the American Academy of Professional Coders.

Kyle Scott is a growth strategist and entrepreneur focused on helping MedTech companies turn complex go-to-market challenges into scalable revenue systems. As the founder of NorthWing Digital, he’s built a firm that partners with commercialization and marketing teams to drive measurable growth through performance marketing, sales enablement, and attribution strategy. NorthWing Digital specializes in helping mid-market MedTech companies launch products, enter new markets, and build marketing engines that actually move the needle.

Broad cross-functional background with deep expertise in Global Market Access and Marketing. Detailed knowledge of global reimbursement and pricing. Strong analytical and planning skills, combined with the ability to coordinate the efforts of many to meet organizational goals. - Over 25 years management & leadership - 12 years Reimbursement & Pricing - 4 years Business Development (M&A) - 3 years defibrillator & pacemaker Sales - 17 years Product Development & Operations background - Highly analytical Marketing & Business Strategy roles

Amrinder Singh is a Partner at Vensana Capital and joined the firm in 2021. Amrinder has nearly two decades of medtech operating and investing experience, ranging from engineering, corporate strategy, and venture capital investing. Prior to Vensana Capital, Amrinder was a Senior Investment Director at Medtronic Ventures where he supported new investments in the medtech and digital health spaces, providing operational and board management support to portfolio companies. Prior to his investment career, Amrinder led Business Development & Strategy for Medtronic’s care management services, helping to shape the vision for Medtronic's value-based healthcare strategy. Amrinder started his career at Medtronic within the Corporate Strategy group. Before joining Medtronic, Amrinder held product management and engineering positions at Thoratec Corporation. Amrinder graduated from University of California, Davis in Biosystems Engineering and earned his MBA from Northwestern University, Kellogg School of Management.

Jayme Strauss is a seasoned healthcare professional with over 15 years of experience at the intersection of clinical excellence, healthcare innovation and commercial strategy. Trained as a neurocritical care ICU nurse, Jayme transitioned into hospital administration and then into leadership within high-growth healthcare startups, where she has consistently built and scaled impactful neuroscience programs and technologies. Strauss became a hospital and healthcare business executive As Chief Clinical and Commercial Officer at Precision Neuroscience, Jayme leads the companies integrated strategy to bring the Layer 7 Brain- Computer Interface (BCI) system from research to real-world clinical adoptionShe is responsible for aligning clinical development, regulatory engagement, and market access, while also overseeing provider education, site training, and commercialization. Under her leadership, Precision secured its first FDA 510(k) clearance, launched pivotal clinical research collaborations, and laid the foundation for multi-year commercialization and reimbursement strategies. Prior to Precision Jayme served as Chief Clinical Officer at Viz.ai, where she played a pivotal role in growing the company from early commercial stage to national scale. She led the development of Viz.ai’s clinical and evidence strategy, secured the first-ever AI New Technology Add-On Payment (NTAP), and helped build a robust life sciences business unit. Her work directly contributed to significant commercial success, real-world evidence generation, and a platform for AI-based care coordination. Earlier in her career, Jayme spent over a decade as a hospital executive at Baptist Health South Florida and Piedmont Healthcare, where she led major neuroscience service line expansions, established high-performing clinical teams, and received national recognition for advancing stroke and neurocritical care delivery. Throughout her career, Jayme has remained focused on bridging the gap between cutting-edge technology and clinical practice. She is passionate about improving patient outcomes, enabling provider adoption, and driving innovation that makes a measurable difference in the lives of patients and their families.

Rich Thompson is a Co-Founder and the President of R&D and Engineering at VitaTek. He brings his 25-year user-centered, product development experience for all types of clients from startups to Fortune 500 companies.

Rich has led the development of over 57 products in the Electrosurgical, Electrophysiology, structured heart, and capital equipment categories.

He is a seasoned leader of multidisciplinary teams running medical, industrial, and consumer development programs.

Courtney is a founding partner of Cooley’s Chicago office, where she advises her clients in equity, debt and other capital markets transactions, as well as corporate governance and securities law matters. She is a trusted adviser to public and private companies across a range of industries, with an emphasis on the technology and life sciences sectors. She also represents top investment banks.

Allison L. Watkins is Founder & CEO of Watkins-Conti Products, Inc. (WCP), a healthcare company that pioneers patient-developed solutions for women's pelvic health. Allison holds numerous patents and trademarks globally. She has raised funds from private investors to create quality management systems, protect her robust intellectual property portfolio, secure contract manufacturing, conduct clinical trials, obtain FDA Clearance for a medical device for stress urinary incontinence, and expand the WCP executive team and expert advisers. An engaging speaker, Allison challenges social taboos around women’s health and well-being. She is passionate about developing treatments that benefit women, and funding for women-led healthcare companies. Allison was recognized in Business Times’ Top 20 under 40, Disrupt magazine’s Top Ten Influential Women, and the Journal Record’s Achievers Under 40. Watkins-Conti Products, Inc. was named Most Promising New Venture for 2021 by Oklahoma Venture Forum, and a Top Ten Nephrology and Urology Company by MedTech Outlook

Lisa Wipperman Heine currently serves on the Board of Directors for several public, private equity, and early-stage, VC-backed medtech/biotech companies. In addition, she has held executive leadership roles in both large medtech companies as well as venture-backed start-ups. Most recently, Lisa was President and Chief Executive Officer at preCARDIA, Inc., an early-stage, heart failure-focused medtech company which was acquired by Abiomed, Inc., in 2021. Ms. Heine also previously served in multiple leadership roles at ev3 and Covidien, Inc., including Global Vice President of Medical Affairs for Vascular Therapies. During her tenure at Covidien, she helped drive the strategy in support of a $1.7B business and was also responsible for leading the strategy and operations of Clinical Affairs, Healthcare Economics, Policy and Reimbursement, and Medical Education functions. Lisa’s current roles include serving as an independent director for Surmodics, Inc. (NASDAQ: SRDX), Miromatrix (NASDAQ: MIRO) and Gradient Denervation Technologies. She also previously served on the board of Natus Medical (NASDAQ: NTUS) which was acquired by the Archimed Group in 2022.

Sarah is the founder and CEO of Melodi Health, a women’s health-focused medical device company partnered with Medtronic to address profound unmet needs for women experiencing breast cancer and related surgical complications. Prior to Melodi, Sarah was a consultant to large multi-national companies helping to develop their R&D pipelines through immersive ethnographic and preclinical research. She began her career in medical device product development at Guidant in 2003 after receiving her degree in Chemical Engineering and Polymer Science from the University of Minnesota and has experienced all aspects of product development throughout her career from concept generation to post-market monitoring. She is passionate about applying her technical degree to practical health issues, particularly in women’s health.

Jennie Xue is a Senior Managing Director on the Healthcare team at Guggenheim Securities where she focuses on M&A advisory, specializing in the medical device space and also digital devices. She was previously at BofA Merrill and Merrill Lynch, with +16 years of experience advising on sellside / buyside M&A and public / private financings for both start-up entrepreneurs as well as multinational strategics. Jennie graduated from the Jerome T. Fisher Program at the University of Pennsylvania with dual degrees from the Wharton School and the School of Engineering.

Darshana is a Founder and Managing Partner of CHV and a member of the firm’s Investment Committee. She is actively involved in all aspects of the fund, including investments and capital raising, and has led investments in the medical device, women’s health and diagnostics markets for over 15 years. Darshana led CHV’s investments in Augmenix (acquired by Boston Scientific), nVision Medical (acquired by Boston Scientific), Maxwell Health (acquired by SunLife), Aria CV, PanTher Therapeutics, AtaCor Medical, Instylla, Avive, Rejoni and Venova Medical. She has represented CHV on the Boards of each of those companies. Prior to joining CHV in 2007, Darshana was an Investigator at Vertex Pharmaceuticals, and an integral part of drug development programs in oncology, metabolic disease, and immunology. Previously she worked at Genome Therapeutics, a Massachusetts-based biotechnology company and at the Dana Farber Cancer Institute. Darshana currently serves as an advisor of the Deshpande Center for Technological Innovation at MIT, (a foundation that helps MIT students and faculty commercialize breakthrough technologies and inventions), as a Board Director of The New England Venture Capital Association (NEVCA) and as a lead advisor to the Portfolia FemTech fund (an investment fund designed for women). Darshana received an M.P.A. from Harvard University, an M.A. in Cell and Molecular Biology from Boston University, and a B.S. in Biochemistry from Bombay University in Bombay, India.